Canadian Scientists Create First TB Vaccine for Cattle

After years of watching farmers lose entire herds to bovine tuberculosis, Canadian scientists have developed a vaccine that could change everything.

Researchers at the University of Saskatchewan's Vaccine and Infectious Disease Organization created MSX-1, a vaccine that protects cattle from bovine TB while still allowing the disease to be detected if it occurs. That second part is crucial because existing vaccines create false positives that make infected animals impossible to identify.

The vaccine protected 80 percent of mice from a highly virulent TB strain in recent trials. Even better, it didn't interfere with the standard tuberculin skin test that farmers and veterinarians rely on to catch infections early.

Lead researcher Jeffrey Chen says the team is now ready to test MSX-1 in actual cattle. The mice faced a much stronger TB strain than what typically appears on farms, so the vaccine should perform even better in real-world conditions.

Current protocol requires farmers to destroy entire herds when bovine TB is detected. Since 2023, cases have appeared across Alberta, Saskatchewan, and Manitoba, devastating family operations and wiping out years of careful breeding work.

The only existing TB vaccine, BCG, has been used in humans for decades but creates a major problem for livestock. Animals vaccinated with BCG test positive for TB whether they're infected or not, making disease detection impossible.

The Ripple Effect

A successful cattle vaccine would be the first of its kind anywhere in the world. No country currently has a licensed bovine TB vaccine that allows for accurate disease testing.

The research team must now prove exactly how MSX-1 works and confirm it's completely safe for animals entering the food chain. They also need to verify the vaccine doesn't affect cattle growth rates, a critical concern for beef producers.

Chen calls it a parallel journey: testing the vaccine in cattle while simultaneously mapping out the immune response it triggers. Both pieces are essential for regulatory approval.

The federal government recently extended tax deferrals for producers affected by bovine TB in 2024 and 2025, acknowledging the financial devastation these outbreaks cause. A working vaccine would eliminate the need for such emergency measures.

If MSX-1 succeeds in cattle trials and gains regulatory approval, Canada will have created something the entire world needs. Chen says it would be the proudest moment of his research career.

The next phase begins soon: isolating common TB strains from actual farms and testing whether this homegrown solution can finally give cattle producers a real defense against a disease that has haunted them for generations.